Dynavax explodes on COVID news, but that’s not why I hold it
What’s a sensible market manager supposed to do when he keeps buying a stock for its commercialization of a Hepatitis vaccine but said stock keeps getting caught up in COVID hype?
Why, in this case take another profit but only on a partial position and hold the rest. Yeah, that sounds about right. I am no genius and have the failures to prove it. But DVAX is one that I have not seemed to be able to fail on over the last couple of years. Mostly the willingness to sell when it gets too far hyped is the reason why. But as noted, this time I’ll reserve some shares.
For “best of breed” top down analysis of all major markets, subscribe to NFTRH Premium, which includes an in-depth weekly market report, detailed interim market updates and NFTRH+ dynamic updates and chart/trade setup ideas. You can also keep up to date with actionable public content at NFTRH.com by using the email form on the right sidebar. Follow via Twitter @NFTRHgt.
